Yap YS, Chiu J, Ito Y, Ishikawa T, Aruga T, Kim SJ, Toyama T, Saeki T, Saito M, Gounaris I, Su F, Ji Y, Han Y, Gazdoiu M, Masuda N.

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer

Cancer Sci. 2020 Sep;111(9):3313-3326. doi: 10.1111/cas.14554. Epub 2020 Jul 28.

[Citation: -] [IF: 6.72 (JCR 2020)]  

​

Dawood S, Chiu JW, Huang CS, Nag S, Sookprasert A, Yap YS, Md Yusof M.

Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.

Curr Med Res Opin. 2020 Aug;36(8):1363-1373. doi: 10.1080/03007995.2020.1783646. Epub 2020 Jul 2.PMID: 32544344

[Citation: -] [IF: 2.58 (JCR 2020)]  

​

Shing K, Kwok G, Chiu J, Cheung TT, Yau T.

Editorial: Sorafenib plus Doxorubicin in Advanced Hepatocellular Carcinoma Patients:  Hope or Hype?

Annals of Translational Medicine 2020;8(24):1695

[Citation: -] [IF: 3.93 (JCR 2020)]  

Xu J, Xu RH, Qin S, Pan H, Bai Y, Chi Y, Wang L, Bi F, Cheng Y, Liu T, Ma D, Shen L, Ba Y, Liang J, Wang X, Yau TCC, Ma BB, Yeh KH, Lin JK, Kappeler C, Shapiro J, Kalmus J, Li J.

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial  
J Gastroenterol Hepatol. 2020 Jan 3

[Citation: 4 ] [IF: 4.03 (JCR 2020)] 

​

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL

KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase 3 trial.
J Clin Oncol. 2020 Jan 20;38(3):193-202.

[Citation: 58 ] [IF: 44.54 (JCR 2020)] 

​

Chiu DK, Yuen VW, Wing-Sum Cheu J, Wei LL, Ting V, Fehlings M, Sumatoh H, Nardin A, Newell EW, Oi-Lin Ng I, Yau TC, Wong CM, Wong CC.
Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. 
Gastroenterology 2020 Apr 7;S0016-5085(20)30461-3.

[Citation: 20 ] [IF: 22.68 (JCR 2020)] 

​

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL, IMbrave150 Investigators. 
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. 
N Engl J Med. 2020 May 14;382(20):1894-1905.

[Citation: 826 ] [IF: 91.25 (JCR 2020)] 

​

Kelley RK, Mollon P, Blanc JF, Daniele B, Yau T, Cheng AL, Valcheva V, Marteau F, Guerra I, Abou-Alfa GK. 
Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. 
Adv Ther. 2020 May 18.

[Citation: 11 ] [IF: 3.85 (JCR 2020)] 

​

Robin Kate Kelley, Saswati Hazra, Jennifer W. Oliver, Ann-Lii Cheng, Thomas Yau, Lorenza Rimassa5. 
Cabozantinib in combination with atezolizumab as first-line therapy for advanced hepatocellular carcinoma: COSMIC-312 phase 3 study design. 
Future Oncology. 2020 Jun 3

[Citation: 17 ] [IF: 3.40 (JCR 2020)] 

​

Zhang BZ, Hu YF, Chen LL, Yau T, Tong YG, Hu JC, Cai JP, Chan KH, Dou Y, Deng J, Wang XL, Hung IF, To KK, Yuen KY, Huang JD. 
Mining of Epitopes on Spike Protein of SARS-CoV-2 from COVID-19 Patients. 
Cell Research 2020 Jul 1:1-3. (Letter)

[Citation: 53 ] [IF: 25.62 (JCR 2020)] 

​

Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. 
Serum alpha-fetoprotein levels and clinical outcome in the phase 3 CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma. 
Clin Cancer Res 2020 Jul 7

[Citation: 8 ] [IF: 12.53 (JCR 2020)] 

​

Dong Y, Liu TH, Yau T, Hsu C. 
Novel systemic therapy for hepatocellular carcinoma (HCC). 
Hepatic international 2020 Jul 13.

[Citation: 6 ] [IF: 6.05 (JCR 2020)] 

​

Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A;NALA Investigators
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. 
J Clin Oncol. 2020 Jul 17:JCO2000147

[Citation: 88 ] [IF: 44.54 (JCR 2020)] 

​

Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A.

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.

Journal of Hepatology, Volume 73, Issue 6, 2020, Pages 1460-1469, ISSN 0168-8278
[Citation: 36 ] [IF: 25.08 (JCR 2020)] 

​

Bao-Zhong Zhang, Hin Chu, Shuo Han, Huiping Shuai, Jian Deng, Ye-fan Hu, Hua-rui Gong, Andrew Chak-Yiu Lee, Zijiao Zou, Thomas Yau, Wutian Wu, Ivan Fan-Ngai Hung, Jasper Fuk-Woo Chan, Kwok-Yung Yuen, Jian-Dong Huang,
SARS-CoV-2 infects human neural progenitor cells and brain organoids. 
Cell Research 2020 Aug 4.  (Letter)

[Citation: 87 ] [IF: 25.62 (JCR 2020)] 

​

Robin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park,Luigi Bolondi, Stephen L. Chan, Ho Yeong Lim, Ari Baron,8 Francis Parnis, Jennifer Knox, Stephane Cattan, Thomas Yau , Julie C. Lougheed, Steven Milwee, Anthony B. El-Khoueiry, Ann-Lii Cheng, Tim Meyer, Ghassan K.
Abou-Alfa
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: A subgroup analysis of the phase 3 CELESTIAL trial. 
ESMO OPEN .2020 Aug;5(4):e000714.

[Citation: 8 ] [IF: 6.54 (JCR 2020)] 

​

Thomas Yau, Yoon-Koo Kang, Tae-You Kim, Anthony B. El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero,  Masatoshi Kudo, Ming-Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel El-Rayes, Mirelis Acosta-Rivera,Ho-Yeong Lim, Jaclyn Neely, Yun Shen, Carlos Baccan, Chiun Hsu. 
Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial 
JAMA Oncology 2020 Oct 1

[Citation: 101 ] [IF: 31.78 (JCR 2020)] 

​

Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, Kudo M. 
Health-Related Quality-of-Life Impact of Pembrolizumab Versus Best Supportive Care in Previously Systemically Treated Patients With Advanced Hepatocellular Carcinoma: KEYNOTE-240. 
Cancer. 2020 Nov 24.

[Citation: 3 ] [IF: 5.24 (JCR 2020)] 

​

Chui AMN, Yau TCC, Cheung TT. 
An overview in management of hepatocellular carcinoma in Hong Kong using the Hong Kong Liver Cancer (HKLC) staging system.
Glob Health Med. 2020 Oct 31;2(5):312-318.

[Citation: - ] [IF: NA] 

​

Saura C, Oliveira M, Kim SB, Yau T, Takano T, Brufsky A. 
Reply to T.J.A. Dekker, D.C. Mo et al, and A. Seidman et al. 
J Clin Oncol. 2020 Dec 17:JCO2002963 (Letter)

[Citation: - ] [IF: 44.54 (JCR 2020)]